期刊文献+

100例异体造血干细胞移植治疗恶性血液病移植前临床特征与预后相关性研究 被引量:2

Impact of pre-transplantation characteristics on the outcome of allogeneic hematopoietic stem cell transplantation in patients with hematological malignancies: a retrospective analysis of 100 cases
下载PDF
导出
摘要 目的:分析异体造血干细胞移植(allo-HSCT)治疗恶性血液疾病移植前的临床特征与移植预后的关系。方法:100例接受allo-HSCT治疗患者中男63例,女37例,中位年龄34(15~55)岁。46例人类白细胞抗原(HLA)相合亲缘供体移植、51例HLA相合非亲缘无关供体和3例半相合亲缘供体移植。其中慢性粒细胞性白血病(CML)24例,急性髓细胞白血病(AML)37例,急性淋巴细胞性白血病(ALL)36例和骨髓增生异常综合征(MDS)3例。处于疾病早期患者78例,进展期患者22例。单因素和多因素方法分析患者年龄、性别、供患者HLA相合、干细胞来源(骨髓、外周血)、供受者性别、移植前疾病状态和诊断-移植时间等因素与移植后总生存(overall survival,OS)率、移植相关病死率(transplantation related mortality,TRM)和复发率(relapserate,RR)的关系。结果:100例患者随访24(1~84)个月,移植后5年预期OS率为(59.9±7.2)%,TRM为(24.9±6.5)%,RR为(22.4±5.9)%。单因素分析提示移植前疾病状态与移植后OS率、TRM、RR相关,诊断-移植时间与移植后OS率、TRM相关。多因素分析提示移植前疾病状态与OS率、RR相关,诊断-移植时间与TRM密切相关。结论:移植前疾病状态和诊断-移植时间对移植治疗的长期生存、复发和不良反应相关,早期移植是提高移植疗效关键。 Objective To assess the impact of pre-transplantation characteristics on the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with hematological malignancies. Methods The outcomes of 100 hematological malignancy patients received allo-HSCT (male 63, female 37; median age 34) were retrospectively analyzed. Forty six patients received allo-HSCT from human leucocyte antigen (HLA)-matched sibling donors and 54 from HLA-matched unrelated donors (n=51) or haploidentical donor (n=3). Twenty-four patients were diagnosed as having chronic myeloid leukemia (CML) and 37 with acute myeloid leukemia (AML), 36 with acute lymphocytic leukemia (ALL) and 3 with myelodysplasia syndrome (MDS). Among these patients, 78 patients were transplanted with disease in early stage and 22 patients in advanced stage. Univariate and multivariate analysis were performed to identify the potential prognostic factors of allo-HSCT outcome in terms of overall survival (OS), transplantation related mortality (TRM) and relapse rate (RR) which include age, sex, donor type, source of stem cell (bone marrow vs peripheral blood), donor/recipient sex mismatch, pre- transplantation disease status and time from diagnosis to transplantation. Results The 100 patients were followed-up for a median of 24(1-84) mouths after transplantation with an estimated 5-year OS rate of (59.9±7.2)%, 5-year TRM of (24.9±6.5)% and 5-year RR of (22.4±5.9)%. Univariate analysis demonstrated that pre-transplantation disease status was correlated with OS, TRM and RR while the time from diagnosis to transplantation was correlated with OS and TRM. Multivariate analysis showed that disease status was the independent prognostic factor for both OS and RR while the time from diagnosis to transplantation was the independent prognostic factor for TRM. Conclusions Pre-transplantation disease status and time from diagnosis to transplantation were the prognostic factors for allo-HSCT in patients with hematological malignancies. Early transplantation is critical for achieving a good long-term outcome.
出处 《内科理论与实践》 2010年第1期57-61,共5页 Journal of Internal Medicine Concepts & Practice
关键词 异体造血干细胞移植 预后 白血病 Allogeneic hematopoietic stem cell transplantation Prognosis Leukemia
  • 相关文献

参考文献17

  • 1Craddock CF.Full-intensity and reduced-intensity allo-geneic stem cell transplantation in AML. Bone Marrow Transplantation . 2008
  • 2Armand P,Kim HT,Cutler CS,et al.A prognostic score for patients with acute leukemia or myelodysplastic syn-dromes undergoing allogeneic stem cell transplantation. Biology of Blood and Marrow Transplantation . 2008
  • 3Gratwohl A.Risk assessment in haematopoietic stem cell transplantation. Bailliere s Best Practice and Research Clinical Haematology . 2007
  • 4Pasquini MC.Impact of graft-versus-host disease on survival. Bailliere s Best Practice and Research Clinical Haematology . 2008
  • 5Chaidos A,Kanfer E,Apperley JF.Risk assessment in haemotopoietic stem cell transplantation:disease and disease stage. Bailliere s Best Practice and Research Clinical Haematology . 2007
  • 6Gratwohl A,Hermans J,Goldman JM,et al.Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet,The . 1998
  • 7Champlin RE,Schmitz N,Horowitz MM,et al.Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood . 2000
  • 8Korbling M,Anderlini P.Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter. Blood . 2001
  • 9A Stein,and SJ Forman.Allogeneic transplantation for ALL in adults. Bone Marrow Transplantation . 2008
  • 10Passweg,JR,Walker,I,Sobocinski,KA,Klein,JP,Horowitz,MM,Giralt,SA.Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants. British Journal of Haematology . 2004

同被引文献14

  • 1徐岚,胡炯,吴文,闫骅,赵维莅,唐,沈志祥.造血干细胞移植治疗血液恶性肿瘤的生存分析[J].肿瘤,2007,27(4):312-315. 被引量:7
  • 2吴德沛,孙爱宁.临床造血干细胞移植.1版.合肥:安徽科学技术出版社,2010:160-167.
  • 3Tachibana T, Takasaki H, Tanaka M, et al. Serum ferritin and disease status at transplantation predict the outcome of allo-SCT in patients with AML or myelodysplastic syndrome. Bone Marrow Transplant ,2011,46 : 150-151.
  • 4Krauter J, Wagner K, Stadler M, et al. Prognostic factors in atlo- SCT of elderly patients with AML. Bone Marrow Transplant ,2011, 46 : 545-551.
  • 5Ramirez P, Brunstein CG, Miller B, et al. Delayed platelet recov- ery after allogeneic transplantation: a predictor of increased treat- ment-related mortality and poorer survival. Bone Marrow Trans- plant ,2011,46:981-986.
  • 6Cao TM, Shizuru JA, Wong RM, et al. Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoi- etic cell transplantation is affected by CD8 + T-cell dose. Blood, 2005,105:2300-2306.
  • 7Solomon SR, Mielke S, Savani BN, et .al. Selective depletion of alloreactive donor lymphocytes : a novel method to reduce the sever- ity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood, 2005,106 : 1123- 1129.
  • 8Mavroudis D, Read E, Cottler-Fox M, et at. CD34 +cell dose predicts survival, posttransplant morbidity, and rate of hemato- logic recovery after allogeneic marrow transplants for hematologic malignancies. Blood, 1996,88 : 3223-3229.
  • 9Verdonck LF,de Gast GC,van Heugten, HG, et at. Cytomegalov- irus infection causes delayed platelet recovery after bone marrow transplantation. Blood, 1991,78:844-848.
  • 10Couban S, Simpson DR, Barnett MJ,et at. A randomized multi- center comparision of bone marrow and peripheral blood in recipi- ents of matched sibling allogeneic transplants for myeloid malig- nancies. Blood ,2002,100 : 1525-1531.

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部